JP2011507891A5 - - Google Patents

Info

Publication number

JP2011507891A5

JP2011507891A5 JP2010539825A JP2010539825A JP2011507891A5 JP 2011507891 A5 JP2011507891 A5 JP 2011507891A5 JP 2010539825 A JP2010539825 A JP 2010539825A JP 2010539825 A JP2010539825 A JP 2010539825A JP 2011507891 A5 JP2011507891 A5 JP 2011507891A5

Authority

JP

Japan

Prior art keywords

antibody

fragment

therapeutic agent

dose

agent according

Prior art date

2008-12-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims description 78
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 45
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 45
• 239000003814 drug Substances 0.000 claims description 27
• 201000005569 Gout Diseases 0.000 claims description 10
• 208000006820 Arthralgia Diseases 0.000 claims description 9
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 9
• 238000010494 dissociation reaction Methods 0.000 claims description 9
• 230000005593 dissociations Effects 0.000 claims description 9
• 239000002464 receptor antagonist Substances 0.000 claims description 5
• 229940044551 receptor antagonist Drugs 0.000 claims description 5
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
• 239000013543 active substance Substances 0.000 claims description 4
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
• 238000003556 assay Methods 0.000 claims description 3
• 239000008280 blood Substances 0.000 claims description 3
• 210000004369 blood Anatomy 0.000 claims description 3
• 230000005764 inhibitory process Effects 0.000 claims description 3
• 230000021995 interleukin-8 production Effects 0.000 claims description 3
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical group N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 2
• 102400000739 Corticotropin Human genes 0.000 claims description 2
• 101800000414 Corticotropin Proteins 0.000 claims description 2
• 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
• 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 2
• 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 2
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 2
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
• 230000001154 acute effect Effects 0.000 claims description 2
• 150000001413 amino acids Chemical class 0.000 claims description 2
• 229960004238 anakinra Drugs 0.000 claims description 2
• 230000001684 chronic effect Effects 0.000 claims description 2
• 229960001338 colchicine Drugs 0.000 claims description 2
• 239000003246 corticosteroid Substances 0.000 claims description 2
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
• 229960000258 corticotropin Drugs 0.000 claims description 2
• 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 2
• 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 2
• 238000010255 intramuscular injection Methods 0.000 claims description 2
• 239000007927 intramuscular injection Substances 0.000 claims description 2
• 238000010253 intravenous injection Methods 0.000 claims description 2
• 230000003472 neutralizing effect Effects 0.000 claims description 2
• 229940124597 therapeutic agent Drugs 0.000 claims 26
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 238000000034 method Methods 0.000 description 76
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000000203 mixture Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1